Ligand Pharmaceuticals Inc (LGND) Stock AnalysisLGNDStock AnalysisLigand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ligand Pharmaceuticals Inc is a good buy right now due to its strong recent earnings performance, with a reported Q2 EPS of $2.22, exceeding expectations by 65.67%. The stock is currently priced at $280.49, with analysts projecting a price target of $390, indicating a potential upside of approximately 39%. Additionally, the company's gross margin is robust at 82.24%, reflecting strong profitability. However, a risk to consider is the RSI at 35.841, indicating potential oversold conditions.

6 analysts cover LGND: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 237.20.